

INDEX

- b H Laborit, P Huguenard, R Allaume
Un nouveau stabilisateur végétatif (LE 4560 RP).
Presse Med 1952; 60: 206-208. 1
- b J Delay, P Deniker, JM Harl
*Utilisation en thérapeutique psychiatrique d'une phénothiazine
d'action centrale élective (4560 RP).*
Ann Med Psychol (Paris) 1952; 110: 112-131. 7
- b S Courvoisier, J Fournel, R Ducrot, M Kolsky, P Koetschet
*Propriétés pharmacodynamiques du chlorhydrate de chloro-3
(diméthylamino-3' propyl)-10 phénothiazine (4.560 R.P.).*
Arch int Pharmacodyn 1953; 92: 305-361. 29
- b E Brandrup, P Kristjansen
A controlled clinical test of a new psycholeptic drug (haloperidol).
J Ment Sci 1961; 107: 778-782. 89
- b PAJ Janssen
The butyrophenone story.
In: FJ Ayd Jr, B Blackwell. Discoveries in biological psychiatry.
Philadelphia (PA): Lippincott Williams & Wilkins; 1970. p. 165-179. 97
- b P Seeman, T Lee, M Chau-Wong, K Wong
Antipsychotic drug doses and neuroleptic/dopamine receptors.
Nature 1976; 261: 717-719. 115
- b A Carlsson
The current status of the dopamine hypothesis of schizophrenia.
Neuropsychopharmacol 1988; 1: 179-186. 119
- b DF Klein, AJ Friedhoff, HY Meltzer, SH Snyder, A Carlsson
*Comments and reply on "The current status of the dopamine
hypothesis of schizophrenia".*
Neuropsychopharmacol 1988; 1: 187-203. 129

- b J Kane, G Honigfeld, J Singer, H Meltzer, and the Clozaril Collaborative Study Group.
Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine.
Arch Gen Psychiatry 1988; 45: 789-796. 147
- b HY Meltzer
Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia.
Psychopharmacology (Berl) 1989; 99: S18-S27. 157
- b GE Crane
Iproniazid (Marsilid®) phosphate, a therapeutic agent for mental disorders and debilitating diseases.
Psychiatric Res Reports 1957; 8: 142-152. 169
- b R Kuhn
The treatment of depressive states with G 22355 (imipramine hydrochloride).
Am J Psychiatry 1958; 115: 459-464. 183
- b BB Brodie, PA Shore
A concept for a role of serotonin and norepinephrine as chemical mediators in the brain.
Ann NY Acad Sci 1957; 66: 631-642. 191
- b IP Lapin, GF Oxenkrug
Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect.
The Lancet 1969; 1: 132-136. 205
- b B Siwers, VA Ringberger, JR Tuck, F Sjöqvist
Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients.
Clin Pharmacol Ther 1977; 21: 194-200. 213
- b DT Wong, FP Bymaster, JS Horng, BB Molloy
A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-ethyl-3-phenylpropylamine.
J Pharmacol Exp Ther 1975; 193: 804-811. 223
- b LO Randall, GAH Schallek, EF Keith, RE Bagdon
The psychosedative properties of methaminodiazepoxide.
J Pharmacol Exp Ther 1960; 129: 163-171. 233

- b JD Christensen
Tolerance development with chlordiazepoxide in relation to the plasma levels of the parent compound and its main metabolites in mice.
 Acta Pharmacol Toxicol (Copenh) 1973; 33: 262-272. 245
- b W Hunkeler, H Möhler, L Pieri, P Polc, EP Bonetti, R Cumin, R Schaffner, W Haefely
Selective antagonists of benzodiazepines.
 Nature 1981; 290: 514-516. 259
- b E Costa, A Guidotti, CC Mao, A Suria
New concepts on the mechanism of action of benzodiazepines.
 Life Sci 1975; 17: 167-185. 265
- b JFJ Cade
Lithium salts in the treatment of psychotic excitement.
 Med J Australia 1949; 2: 349-351. 287
- b M Schou, N Juel-Nielsen, E Strömngren, H Voldby
The treatment of manic psychoses by the administration of lithium salts.
 J Neurol Neurosurg Psychiat 1954; 17: 250-260. 293
- b PC Baastrup, M Schou
Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis.
 Arch Gen Psychiatry 1967; 16: 162-172. 307
- b ER Hart
N-allyl-norcodeine and N-allyl-normorphine, two antagonists to morphine.
 J Pharmacol Exp Ther 1941; 72: 19. 321
- b VP Dole, M Nyswander
A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride.
 JAMA 1965; 193: 646-650. 325
- b A Goldstein, LI Lowney, BK Pal
Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain.
 Proc Natl Acad Sci USA 1971; 68: 1742-1747. 333
- b CB Pert, SH Snyder
Opiate receptor: Demonstration in nervous tissue.
 Science 1973; 179: 1011-1014. 341

- b J Hughes, TW Smith, HW Kosterlitz, LA Fothergill, BA Morgan, HR Morris
*Identification of two related pentapeptides from the brain
with potent opiate agonist activity.*
Nature 1975; 258: 577-579. 347
- b WA Devane, FA Dysarz III, M Ross Johnson, LS Melvin, AC Howlett
Determination and characterization of a cannabinoid receptor in rat brain.
Mol Pharmacol 1988; 34: 605-613. 353
- b A Hofmann
Psychotomimetic drugs: Chemical and pharmacological aspects.
Acta Physiol Pharmacol Neerl 1959; 8: 240-258. 365
- b ED Luby, BD Cohen, G Rosenbaum, JS Gottlieb, R Kelley
Study of a new schizophrenomimetic drug - Sernyl.
AMA Arch Neurol Psychiatry 1959; 81: 363-369. 387
- b EF Domino, P Chodoff, G Corssen
Pharmacologic effects of CI-581, a new dissociative anesthetic, in man.
Clin Pharmacol Ther 1965; 6: 279-291. 397
- b A Wikler
*Dynamics of drug dependence: Implications of a conditioning
theory for research and treatment.*
Arch Gen Psychiatry 1973; 28: 611-616. 413
- b G Deneau, T Yanagita, MH Seevers
*Self-administration of psychoactive substances by the monkey:
A measure of psychological dependence.*
Psychopharmacology (Berl) 1969; 16: 30-48. 421